Acral Lentiginous Melanoma Treatment Market

Acral Lentiginous Melanoma Treatment Market

Global Acute Acral Lentiginous Melanoma Treatment Market reached US$ YY billion in 2022 and is expected to reach US$ YY million by 2031 growing at a CAGR of YY% during the forecast period 2024-2031.

Acral lentiginous melanoma (ALM) is a specific type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails. Subungual melanoma, a variant of acral lentiginous melanoma occurs beneath the nails and can appear as a dark streak or discoloration.

Some cases of acral lentiginous melanoma have specific genetic mutations that can be targeted with certain therapies. For example, BRAF and NRAS mutations are among those that can be present in some cases. Acral lentiginous melanoma is more common in individuals with darker skin tones, including people of African, Asian, and Hispanic descent.

Market Dynamics

Increasing incidence of skin cancers

The increasing prevalence of skin cancers acts as a significant driver for market growth. Prolonged and intense exposure to ultraviolet (UV) radiation from the sun is a major risk factor for melanoma. Changes in sun exposure patterns, including increased outdoor activities or recreational sun exposure, can contribute to a higher incidence.

For instance, according to the World Health Organization Report, around 132,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime.

Additionally, in 2021, melanoma of the skin was the tenth most common cause of cancer death in Australia. It became the eleventh most common cause of death from cancer in 2023. In 2021, there were 1,455 deaths from melanoma of the skin in Australia (958 males and 497 females).

Furthermore, significant growth drivers such as the increasing awareness regarding advanced melanomas, the rising geriatric population, and increasing advancements in research and development are expected to drive the market in the forecast period.

Side effects of treatment drugs

Vemurafenib drug is used to treat melanoma that has spread and cannot be removed by surgery. This drug can cause blistering, peeling, or loosening of the skin, bloody urine, chills, diarrhea, nausea, and lower back pain. Also, dabrafenib can cause gastrointestinal upset and fatigue in some individuals. Thus, the above factors can hamper the market growth.

Segment Analysis

The global acral lentiginous melanoma treatment market is segmented based on treatment, end users and region.

The BRAF inhibitors segment accounted for approximately 56.6% of the market share

The BRAF inhibitors segment is expected to hold the largest market share over the period forecast. BRAF inhibitors are a class of medications used in the treatment of melanoma, particularly for individuals with specific genetic mutations in the BRAF gene. BRAF inhibitors, particularly dabrafenib and vemurafenib, have demonstrated efficacy in treating melanomas with BRAF mutations. They can lead to tumor shrinkage and improved outcomes in certain patients.

Acral lentiginous melanoma cases with BRAF mutations have shown positive responses to BRAF inhibitors. These drugs work by targeting the overactive BRAF protein by inhibiting the signaling pathway that promotes cancer cell growth. BRAF inhibitors are also used in combination with MEK inhibitors (e.g., trametinib) to enhance treatment efficacy and potentially delay the development of resistance. This combination therapy has shown benefits in acral lentiginous melanoma treatment.

Geographical Analysis

North America is expected to hold a significant position in the acral lentiginous melanoma treatment market share

The global acral lentiginous melanoma treatment market is segmented into North America, Europe, Asia Pacific, South America, the Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the increasing prevalence of ARDS, clinical trials, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Academy of Dermatology Association report, it is estimated that approximately 9,500 people in the U.S. are diagnosed with skin cancer every day. It is estimated that 197,700 new cases of melanoma, 97,920 noninvasive and 99,780 invasive, will be diagnosed in the U.S. in 2022.

Additionally, according to the Canadian Skin Cancer Foundation, over 80,000 cases of skin cancer are diagnosed in Canada each year, and more than 5,000 of these are melanoma which is the deadliest form of skin cancer. Hence, owing to the increasing cases of melanomas, it accelerate the region's growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the global acral lentiginous melanoma treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, drug launches, and consultations worldwide. With the outbreak of the pandemic, many treatment centers faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the acral lentiginous melanoma treatment market was moderately affected over the forecast period.

Market Segmentation

By Treatment
• KIT inhibitors
imatinib
sunitinib
dasatinib
nilotinib
• BRAF inhibitors
vemurafenib
dabrafenib
• Surgery
• Others

By End User
• Hospital
• Oncology Centers
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Genentech Inc., Global Calcium Pvt Ltd., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited, Novartis AG, Dr. Reddy's Laboratories, Array BioPharma Inc., Bristol-Myers Squibb Company, and Aetos Pharma Private Limited among others.

Why Purchase the Report?
• To visualize the global acral lentiginous melanoma treatment market segmentation based on treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global acral lentiginous melanoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global acral lentiginous melanoma treatment market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies